Compare ADMA Biologics Inc (ADMA) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs NRG Energy Inc — how do they compare? ADMA Biologics Inc trades at $13.13 (market cap $2.49B), while NRG Energy Inc trades at $83.51 (market cap $20.23B). The key difference: NRG Energy Inc is far larger — about 8.1× ADMA Biologics Inc's market cap, and NRG Energy Inc pays a 1.97% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ADMA Biologics Inc for 20 Days and NRG Energy Inc for 65 Days on average.
| ADMA | NRG | |
|---|---|---|
Market Cap | $2.49B | $20.23B |
Volume | 5,055,797 | 3,878,773 |
Sector | Health | Utilities |
52-Week High | $20.38 | $184.03 |
52-Week Low | $7.60 | $92.31 |
Typical Hold Time | 20 Days | 65 Days |
Enterprise Value | $2.56B | $44.19B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $11.11, up 0.45% today, with a bullish technical signal from moving averages and strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings showed a Q4 2025 beat but misses in Q1 and Q2 2026, while analyst consensus is strongly positive with 90% buy ratings. The stock faces headwinds from ongoing legal investigations into the board's fiduciary duties, as reported by multiple law firms in August and September 2026.
The outlook remains cautiously optimistic given high analyst buy ratings and projected earnings growth, but legal overhangs and recent earnings misses present near-term risks. Upside potential hinges on Q3 2026 results meeting the expected $0.1967 EPS and resolution of governance concerns.
NRG Energy trades at $96.26, up 1.73% on the day, but remains in a bearish technical trend with key resistance at $97. Fundamentally, the company reported revenue of $30.71 billion in 2025 with a net income margin of 2.56%, though recent Q2 2026 earnings missed expectations. A significant 1.2 GW Texas data center power project represents a major growth initiative, as highlighted in recent earnings calls.
The investment outlook is mixed: strong analyst consensus (71% buy rating) and a $172.43 price target suggest substantial upside, but recent earnings misses and a high debt-to-asset ratio of 56.42% pose risks. The stock's near-term direction hinges on Q3 2026 earnings delivery against a $3.35 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
